PHARMAESSENTIA CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 417 TWD | -0.48% |
|
-1.65% | +20.52% |
| May. 27 | Pharmaessentia Corporation Announces Term Expiration of Their Fourth Remuneration Committee | CI |
| May. 27 | Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee | CI |
| Sales 2024 * | 8.77B 270M | Sales 2025 * | 12.93B 398M | Capitalization | 138B 4.26B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.63B 50.15M | Net income 2025 * | 4.25B 131M | EV / Sales 2024 * | 13.6 x |
| Net cash position 2024 * | 18.94B 583M | Net cash position 2025 * | 19.2B 592M | EV / Sales 2025 * | 9.22 x |
| P/E ratio 2024 * |
84.7
x | P/E ratio 2025 * |
32.7
x | Employees | 131 |
| Yield 2024 * |
0.52% | Yield 2025 * |
0.36% | Free-Float | 74.31% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.48% | ||
| 1 week | -1.65% | ||
| 1 month | +42.08% | ||
| 3 months | +26.94% | ||
| 6 months | +14.40% | ||
| Current year | +20.52% |
1 week
415.00
434.00
1 month
297.00441.00
Current year
281.00441.00
1 year
274.00441.00
3 years
69.00622.00
5 years
53.60622.00
10 years
45.16622.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
CEO | Chief Executive Officer | - | 02-12-31 |
Hsueh Ling Chang
DFI | Director of Finance/CFO | - | 15-10-13 |
Lih-Ling Lin
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Patrick Yang
BRD | Director/Board Member | 75 | 14-02-28 |
Tien Chang
BRD | Director/Board Member | - | 06-06-29 |
Ching Liu Chan
CHM | Chairman | - | 03-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 21 M€ | +11.17% | ||
| 0.12% | 0 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 417 | -0.48% | 2,149,487 |
| 24-05-30 | 419 | -1.53% | 726,152 |
| 24-05-29 | 425.5 | -0.58% | 639,017 |
| 24-05-28 | 428 | +0.94% | 734,961 |
| 24-05-27 | 424 | -.--% | 831,897 |
End-of-day quote Taiwan S.E., May 30, 2024
More quotes
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
417
TWD
Average target price
428.2
TWD
Spread / Average Target
+2.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.52% | 4.26B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- 6446 Stock
